Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha maintains a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $48 to $66.
June 20, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha maintains a Buy rating on Mirum Pharmaceuticals and raises the price target from $48 to $66.
The Buy rating and increased price target from a reputable analyst at Stifel is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100